As a drug development company, CombinatoRx Singapore intends to focus on developing a range of preclinical and clinical development capabilities using CombinatoRx’ combination high throughput screening (cHTS) technology.
The new company has plans to employ around 20 full-time researchers and is expected to commit $20 million to the development of novel drug candidates for infectious diseases.
“CombinatoRx’s technology may accelerate the discovery and development of product candidates designed to target multiple biological pathways,” commented Swee-Yeok Chu, CEO of Bio*One Capital. “Bringing CombinatoRx’s unique competitive advantages to Singapore will position Singapore as a source of innovative new therapeutics to address the large infectious disease market.”
The deal will also put biopharmaceutical firm CombinatoRx in touch with Asian scientific and business communities as Bio*One Capital has agreed to provide the Boston-based company with contacts and links to established companies and research institutes in the region. This support will allow CombinatoRx to expand its pipeline in one of the largest global disease markets, as CombinatoRx president and CEO Alexis Borisy, pointed out.